Bacteriocins & Lantibiotics CDMO Services

Bacteriocins & Lantibiotics (Colicins, Nisin) — Manufacturing CDMO

Microbial precision. Audit-ready delivery. Own the narrow queries—bacteriocin CDMO, lantibiotic CDMO, nisin manufacturer—with a partner that builds the entire path from strain design to aseptic DP, and makes the journey feel effortless.

Executive Summary

Bacteriocins and lantibiotics convert microbial intelligence into manufacturable therapies and high-value ingredients. Colicins (and microcins) from Gram-negative producers deliver receptor-targeted killing in the gut and on surfaces; nisin and other lantibiotics target lipid II with unusual resilience to resistance—at low pH they remain remarkably heat-stable, formulation-friendly peptides. The challenge is not whether they work, but how to build a phase-appropriate manufacturing system—from secretion optimization and IEX/HIC purification to validated potency and release—that satisfies food, feed, or GMP drug expectations.

At Mika Biologics, we are a microbial-first CDMO. We design and run dual manufacturing tracks:

  • Food-grade / feed (GRAS/QPS-aligned, HACCP/ISO 22000/FSSC 22000 frameworks), where nisin E234 and other bacteriocins function as antimicrobial process aids or ingredients.
  • GMP medicinal (21 CFR 210/211; EU GMP Annex 1 for aseptic), where bacteriocins/lantibiotics are drug substances and drug products with full CMC narratives, stability, PPQ, and CPV.

We make both paths feel coherent: same engineering discipline, different documentation cadence. You get the elegance of a single platform with the regulatory texture your program needs.

What We Make (and Where It Fits)

  • Nisin (A/Z variants) and other lantibiotics from Lactococcus or engineered yeasts—bench to pilot to GMP-ready. Mechanism: dual action via lipid II binding → pore formation + cell-wall biosynthesis arrest, a target unlikely to be bypassed easily—hence durable activity.
  • Colicins and microcins from E. coli or heterologous hosts: narrow-spectrum antimicrobials with tunable receptor biology (e.g., BtuB, Tsx) and SOS-controlled expression cassettes; modern applications include microbiome sculpting, decolonization, and bioindustrial hygiene.
  • Food/feed antimicrobials (e.g., nisin E234): ingredient-grade production under food code with specifications that mirror CFR listings and EFSA opinions; optional clean-label narratives.
  • Therapeutic or device-adjacent bacteriocins: sterile DP, combination products (e.g., nisin-coated matrices), and aseptic fill in vials/PFS/cartridges with Annex 1 (2022) practices. (See our Formulation & Aseptic Fill-Finish page for CCIT/lyo strategies.)

Program Architecture — From Design to Aseptic D

Strain & Pathway Design

Choice of producer.

  • Lantibiotics: L. lactis remains the workhorse (native post-translational machinery; NisBTC maturation), but we also deploy Pichia for secretion-led DSP simplicity or glyco-shielding needs. Nisin-regulated expression (NICE) remains a flexible chassis for producing other proteins as well (e.g., lysostaphin), enabling multi-product facilities to retain common toolchains.
  • Colicins/microcins: Native E. coli producers (defined plasmid loci) or clean heterologous hosts with toxin-immunity pairing; we engineer induction systems to decouple production from autolysis and mitigate SOS-linked variability.

Regulatory positioning (food vs. drug).

  • Food/feed track: leverage 21 CFR 184.1538 for nisin preparations; align with GRAS processes and FSIS safe & suitable ingredient tables for meat/poultry uses.
  • Medicinal track: QbD mapping from QTPP → CQAs → CPPs on day one; establish bank governance, comparability logic, and impurity story suitable for IND/CTA assembly.

Genetics & stability.

  • Integrated vs. plasmid systems; copy number control; multi-locus insertion to stabilize output; immunity gene calibration (nisI/nisFEG; colicin immunity genes).
  • GMO handling: risk assessments that cleanly separate food-grade non-GMO nisin from engineered medicinal programs; EU dossier-ready narratives.
Build faster, ferment Smarter, Mika Biologics

Upstream (USP) — Microbial Calm at Scale

Fermentation modes.

  • Lantibiotics: pH-controlled batch/fed-batch in lactic media; strong productivity at mildly acidic pH; oxygen transfer and redox tuning prevent unintended stress responses that dampen nisin synthesis. Process intensification with perfusion-like bleed is available for high space-time yields.
  • Colicins/microcins: Two-phase strategies (biomass → induction) to separate growth from toxin expression; carbon limitation or targeted SOS induction where biology requires it—kept reproducible via e-batch recipes and historian-driven guardrails.

IPC (in-process controls).
Biomass kinetics, pH/redox, temperature ramps; nisin activity (AU/mL) online surrogates via micro-bioassay; plasmid maintenance; immunity gene expression balance for colicins.

Banking.
MCB/WCB with identity (WGS for drug track), phenotypic stability (activity per OD), and freedom from prophages or transmissible resistances (drug track) per EFSA/FDA expectations. EFSA QPS status for Lactococcus strains simplifies food claims when criteria are met.

Downstream (DSP) — Secretion Optimization → IEX/HIC → Polishing

Secretion & capture.

  • Lantibiotics: If secreted, we capture directly from clarified broth; if cell-associated, we apply controlled acid extraction (classic for nisin) followed by ion exchange to concentrate and de-salt.
  • Colicins/microcins: Depending on size/charge, we use cation/anion exchange to concentrate from supernatants, or tag-assisted affinity for heterologous systems with tag removal during polishing.

Core trains.

  • IEX → HIC as the backbone (often with ammonium sulfate feed-in to sharpen HIC selectivity), finishing with SEC or ultrafiltration/diafiltration (UF/DF) to set the final buffer and remove aggregates. Reviews consistently report salt precipitation + IEX/HIC as cost-effective for bacteriocins at scale.
  • Orthogonal polish: mixed-mode resins for stubborn host peptides; membrane adsorbers for endotoxin when using Gram-negative hosts; ATPS can be piloted for CAPEX-light capture when solvent systems are acceptable.

Analytics that steer DSP.

  • Potency by agar-diffusion or turbidimetry reported as AU/mL or activity units/mg;
  • Identity by LC-MS/MS and intact mass;
  • Purity/aggregates by UHPLC/SEC-MALS;
  • Charge variants by IEX profiling;
  • Endotoxin (USP <85> LAL or USP <86> recombinant BET)—critical for drug-track colicins from E. coli.

4) Formulation Development

Nisin/lantibiotics favor slightly acidic systems: histidine/citrate/phosphate buffers in the pH 4–6 range commonly preserve activity and minimize deamidation/oxidation; sugars and polyols tame aggregation and improve lyo-cake integrity for DP. Colicins often require neutral buffers with tighter oxidation control and surfactant policies justified by container–closure data. Mechanistic studies support lipid II binding as the durable pharmacology anchor; formulation protects that action from environmental noise.

For DP and isolator filling, see our Formulation & Aseptic Fill-Finish service—Grade A isolators, CCIT, lyo cycles, and high-concentration syringe handling are standard.

Aseptic Fill-Finish (Vials, PFS, Cartridges)

  • Grade A isolators, Grade B background; media fills and EM to EU Annex 1 (2022) expectations; sterile filtration validated (or closed aseptic processing when peptide size/aggregation precludes 0.22 µm).
  • CCIT: dye ingress, helium leak, deterministic methods as route-appropriate;
  • Presentation: RTU vials, stoppers, PFS barrels compatible with acidic buffers for lantibiotics; silicone oil control for PFS glide force and subvisible particles.

Stability (ICH) and Reference Standards

  • Stability per ICH Q1A(R2): long-term (2–8 °C for most DPs), accelerated, and stress (light, heat, freeze–thaw); nisin’s acidic pH stability enables heat stress outlier tolerance that can simplify distribution narratives in food/feed.
  • Reference standards: activity-traceable internal standards with bracketing to LC-MS identity and AU/mL bioassay; trending in our LIMS so your CPV dashboard “just works” when you scale. (See our Analytical & QC for Microbial Biologics page for the full method catalog.)

Food-Grade vs. GMP Tracks — One Platform, Two Temperatures

Food / Feed (Ingredient) Track

  • Regulatory footing: 21 CFR 184.1538 (nisin preparation) + GRAS inventory precedents and FSIS 7120.1 tables for meat/poultry uses; EU: E234 with EFSA re-evaluation confirming safety under new toxicology.
  • Quality system: HACCP, ISO 22000/FSSC 22000; contaminant specs framed for ingredient markets; process validation leans statistical and microbiological rather than PPQ formalism.
  • Label and claims: clean-label options; natural fermentation narratives; optional OMV marketing avoidance for medical claims.

GMP (Medicinal) Track

  • Regulatory footing: 21 CFR 210/211; EU GMP; Annex 1 (aseptic); full CMC Module 3 with PPQ (three consecutive lots), CPV dashboards, and stability commitments.
  • Controls: DS/DP specs include identity/purity, activity, endotoxin, sterility (USP <71>), subvisible particles, residual DNA/proteins as appropriate; container–closure verified by CCIT.

Analytical Menu

Identity & structure

  • Intact mass (LC-MS), peptide mapping, lantibiotic ring verification where applicable (MS/MS fragments indicative of lanthionine bridges), N-terminus processing.

Potency

  • Agar diffusion (zones) calibrated to AU/mL; turbidimetry kinetic kill; MIC/time-kill against a defined panel (clinical Listeria, Staph, Enterococcus, E. coli targets for colicins).
  • Mechanism-adjacent assays for lantibiotics (lipid II-doped liposome leakage) to support MoA narratives.

Impurities & safety

  • Host proteins (ELISA/HCP), host DNA (qPCR/ddPCR), endotoxin (USP <85>/<86>), bioburden, sterility (USP <71>).

Physicochemical

  • pH/osmolality, SEC-MALS (aggregates), DLS (hydrodynamics), charge variants (IEX), moisture for lyo cakes (Karl Fischer), residual solvents/salts (if ATPS or HIC was used).

Process Characterization, PPQ, and CPV

We run scale-down models that reproduce shear/salt/temperature histories, quantify CPP windows (pH, conductivity, salt gradients, residence time), and map CQAs (potency, purity, aggregates, endotoxin). Three-batch PPQ concludes with a defensible statistical envelope; CPV ties historian tags (conductivity curve shapes, column pressure, flux) to release performance—an early-warning system you can show an inspector with pride. (Deep dive on our Process Characterization, PPQ & CPV for Microbial Platforms page.)

Costing & Timelines (Illustrative)

  • Feasibility (6–10 wks): expression/secretion screens; capture/IEX trials; basic activity and stability scouting; draft control strategy.
  • Process Development (8–14 wks): DoE on feed/induction (USP) and IEX/HIC/UF-DF (DSP); formulation screens; analytical methods qualified.
  • GMP Campaign (8–12 wks): MBRs/eBRs issued; three DS lots; DP fills (vials/PFS) with EM trending and media fills on record; stability initiated.
  • Regulatory Package: spec tables, method validations, PPQ protocol, comparability (for variant or site changes).

Why Bacteriocins & Lantibiotics Now

  • Mechanism resilience: lipid II is fundamental; lantibiotics bind PPi and sequester the precursor, lowering resistance risk relative to classical antibiotics.
  • Narrow-spectrum precision: colicins/microcins can be tuned to spare commensals; emerging datasets show ubiquity and functional breadth—ideal for microbiome-aware strategies.
  • Manufacturing maturity: decades of nisin ingredient production + modern DSP (membrane adsorbers, monolith IEX) shrink COGS and make GMP peptide campaigns predictable.

Interlinks (so search engines—and reviewers—triangulate)

  • When your bacteriocin becomes a sterile drug product, slide over to Formulation & Aseptic Fill-Finish (Grade A Isolators) for lyo cycles, CCIT, and syringe work.
  • For method depth and sample COAs, explore Analytical & QC for Microbial Biologics.
  • If your program crosses into live consortia, Engineered Probiotics (LBP) GMP can share suites and shorten your total calendar.

Representative COA Elements (Examples)

Ingredient-grade nisin: assay (IU or AU/g), purity (%), pH (10% soln), moisture, sodium chloride content, microbiology (TPC, yeast/mold, pathogens), heavy metals; optional E-number declaration and carrier composition aligned to CFR listing.

GMP colicin DP: identity (LC-MS/MS), potency (AU/mL and MIC), purity (UHPLC), aggregates (SEC-MALS), endotoxin, bioburden/sterility, subvisible particles, residual DNA/proteins, appearance, pH/osmolality, container–closure integrity.

Case-Style Patterns

  • Nisin A (ingredient route): Acid extraction + CEX → HIC; lyo DP at pH 4.5 retained >95% activity over 6 months 2–8 °C; heat challenge at 60 °C × 30 min showed <10% loss—consistent with literature that low-pH environments stabilize lantibiotics against heat.
  • Colicin E-variant (GMP route): Heterologous expression with immunity co-expression; AEX capture → HIC polish; rBET endotoxin → <0.5 EU/mg; DP in neutral buffer, surfactant-free, with aggregate control by SEC-MALS; three-batch PPQ met potency & purity CQAs with ≤5% RSD lot-to-lot.

FAQ

Q1. Is nisin really “approved,” and for what?
A. In the U.S., 21 CFR 184.1538 affirms certain nisin preparations as GRAS for specified food uses (e.g., cheese spreads), and industry practice extends via GRAS notices and FSIS tables for meat/poultry contexts. In the EU, nisin is E234, with EFSA’s 2017 re-evaluation supporting safety for proposed uses. Medicinal use is a different pathway (GMP drug), which we support with full CMC.

Q2. How do you purify bacteriocins cost-effectively?
A. Most programs succeed with salt precipitation → IEX → HIC → UF/DF, optionally capped by SEC or membrane polishing. Literature repeatedly identifies IEX/HIC as the economical heart of bacteriocin DSP; we confirm by DoE at lab- and pilot-scale, then lock recipes for GMP.

Q3. Do colicins/microcins need endotoxin testing?
A. Yes—E. coli hosts demand BET. We justify USP <85> LAL or USP <86> recombinant methods, set acceptance criteria based on route/dose, and design the process to remove LPS (AEX/membrane adsorbers + low-LPS media).

Q4. What defines potency—AU, MIC, or both?
A. We report AU/mL for historical continuity (agar diffusion/turbidity) and MIC/time-kill for clinical relevance, indexed to a defined panel. For lantibiotics, we can add lipid II-model leakage as a mechanistic adjunct.

Q5. How stable is nisin?
A. At acidic pH, nisin is notably heat-stable; at neutral pH it’s more labile. Our ICH programs reflect intended route and packaging; for ingredient use, acidic lyo DP often unlocks distribution flexibility. EFSA’s scientific opinion and decades of food use support this profile.

Q6. Can you manufacture both “clean-label” nisin and a GMP bacteriocin?
A. Yes—dual track is our model. We maintain separate quality systems and documentation (food vs. drug), while reusing engineering know-how so you don’t pay twice in calendar or dollars.

Q7. Are Lactococcus producers “safe” by default?
A. Not automatically, but EFSA QPS recognizes Lactococcus species as suitable for the QPS approach when strain-level criteria are met. We document the strain journey either way—QPS/GRAS (food) or full GMP characterization (drug).

Q8. What about resistance and spectrum?
A. Lantibiotics target lipid II—an essential, conserved precursor—reducing resistance avenues; colicins/microcins are precise, enabling microbiome-sparing strategies. We design panels and passage studies to quantify both breadth and durability.

Q9. How do you handle aseptic DP for peptides?
A. Grade A isolators; sterilizing filtration validated (or closed aseptic if filtration is contraindicated); CCIT by deterministic methods; Annex 1 EM trending visible in CPV dashboards.

Q10. Can you interoperate with engineered probiotic programs?
A. Yes—many clients co-develop Engineered Probiotics (LBP) with bacteriocins as effectors. We share suites, analytics, and release logic to compress total time-to-clinic.